DIAH

DIAH 2026

19 – 21 May 2026 | Bruges, Belgium

Charles Owen

CEO / Founder 272BIO

272BIO Limited

Reading, United Kingdom

24 profile visitsSpeakerAcademia / TTO / Emerging Companies / Public Research Organisation / Non-profit Oganisation

Founder of 272BIO with 30 years developing antibody drugs. Track record of taking drugs from initial concept to regulatory approval. 272BIO is a team of industry experts building a growing pipeline of clinically-validated VHH antibody-based medicines.

My organisation

272BIO Limited

272BIO Limited

Reading, United Kingdom

272BIO is a UK-Belgium based antibody discovery and development company with full in-house CMC process development capability. The company is focused and has a track-record of developing differentiated products with a competitive advantage for indications and opportunities across animal health
Read more

About me

Additional questions

Interests

Pharmaceutical / TherapeuticsLivestockCompanion animalsAgro-Food Tech

Speaker sessions (1)

Wednesday, 20 May 2026

14:45 - 15:30

Masterclass 7: Beyond Monoclonal Antibodies: Next Generation Therapeutics for Animal Health - Multi-specificity for Complex Disease and Other Opportunities

Location:BMCC - 3rd Floor - Turtle RoomTrack:Masterclass

This talk explores the next generation of protein therapeutics designed for complex, multi-pathway diseases.

Sign-ups available from 1 Apr 2026, 00:00 to 20 May 2026, 15:30